|Bid||374,500.00 x 0|
|Ask||375,000.00 x 0|
|Day's range||371,000.00 - 389,500.00|
|52-week range||139,500.00 - 538,000.00|
|Beta (5Y monthly)||0.92|
|PE ratio (TTM)||N/A|
|Earnings date||28 Jul 2021 - 02 Aug 2021|
|Forward dividend & yield||1,500.00 (0.42%)|
|Ex-dividend date||29 Dec 2020|
|1y target est||183,455.00|
GC Pharma (006280.KS) today announced that the United States Food and Drug Administration (FDA) accepted the company’s Biologics License Application (BLA) for 'GC5107 (Immune Globulin Intravenous (Human),10% Liquid)’ intended for the treatment of Primary Humoral Immunodeficiency (PI), a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system.
GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2021.
GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, participates in a campaign to celebrate World Hemophilia Day.